Green Cross Medical Science Corporation

A142280

KR7142280007

Medical Equipment, Supplies & Distribution

End-of-day quote Korea S.E. Other stock markets 03:30:00 23/05/2024 am IST			5-day change	1st Jan Change
4,085 ^KRW	-0.12%		0.00%	-14.36%

2023	Green Cross Medical Science Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
2022	Green Cross Medical Science Corporation announced that it has received KRW 30 billion in funding from Daishin Securities Co. Ltd., Investment Arm and other investors	CI

GreenCross Medical Science Corp. has filed an IPO in the amount of KRW 11.20 billion.

September 17, 2014 at 09:30 am IST

Latest news about Green Cross Medical Science Corporation

Green Cross Medical Science Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	15/23/15	CI
Green Cross Medical Science Corporation announced that it has received KRW 30 billion in funding from Daishin Securities Co. Ltd., Investment Arm and other investors	04/22/04	CI
Green Cross Medical Science Corporation announced that it expects to receive KRW 30 billion in funding from Daishin Securities Co. Ltd., Investment Arm and other investors	27/22/27	CI
Oxford Immunotec Global PLC Enters into A Memorandum of Understanding Green Cross Medical Science Corp. to Market the T-SPOT Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea	08/21/08	CI
Hemotune AG announced that it has received CHF 5.1 million in funding from Green Cross Medical Science Corporation, ZKB Start-up Finance, Occident Group AG	23/20/23	CI
Green Cross Medical Science Enters into Co-Development Agreement with GeneCast to Develop A New COVID-19 Detection Kit	24/20/24	CI
GreenCross Medical Science Corp. cancelled the acquisition of additional 29.54% stake in CERAGEM Medisys, Inc.	17/19/17	CI
GreenCross Medical Science Corp. agreed to acquire additional 29.54% stake in CERAGEM Medisys, Inc for KRW 4.6 billion.	17/18/17	CI
GreenCross Medical Science Corp. announced that it has received KRW 10 billion in funding from KB Securities Co., Ltd., Investment Arm and other investors	05/18/05	CI
GreenCross Medical Science Corp. announced that it has received KRW 10 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, and other investors	05/18/05	CI
GreenCross Medical Science Corp. announced that it expects to receive KRW 10 billion in funding from Kiwoom Securities Co., Ltd., Investment Arm, Korea Investment & Securities Co., Ltd., Investment Arm, Industrial Bank of Korea, Investment Arm, and other investors	03/18/03	CI
GreenCross Medical Science Corp. announced that it expects to receive funding from KB Securities Co., Ltd., Investment Arm and other investors	03/18/03	CI
Tranche Update on GreenCross Medical Science Corp.'s Equity Buyback Plan announced on March 2, 2017.	15/17/15	CI
GreenCross Medical Science Corp.'s Equity Buyback announced on March 2, 2017 has closed with 50,000 shares, representing 0.52% for KRW 536.95 million.	10/17/10	CI
GreenCross Medical Science Corp. announces an Equity Buyback for 50,000 shares.	02/17/02	CI
GreenCross Medical Science Corp. authorizes a Buyback Plan.	02/17/02	CI
GreenCross Medical Science Corp. completed the acquisition of 21.06% stake in CERAGEM Medisys, Inc.	31/15/31	CI
GreenCross Medical Science Corp. agreed to acquire a 21.06% stake in CERAGEM Medisys, Inc. for KRW 5 billion.	20/15/20	CI
GreenCross Medical Science Corp. has completed an IPO in the amount of KRW 12.00 billion.	15/14/15	CI
GreenCross Medical Science Corp. has filed an IPO in the amount of KRW 11.20 billion.	17/14/17	CI
GreenCross Medical Science Corp. has withdrawn its IPO.	16/14/16	CI

Chart Green Cross Medical Science Corporation

Duration

Period

Chart Green Cross Medical Science Corporation

More charts

Green Cross Medical Science Corporation is a Korea-based company principally engaged in the medical business. The Company mainly operates its business through three segments: diagnosis reagent segment, blood bag segment and blood dialysate segment. Its diagnosis reagent segment provides in vitro diagnosis reagents and medical equipment. Its blood bag segment provides filter bags and blood bags. The Company distributes its products within domestic market and to overseas markets.

Sector

Medical Equipment, Supplies & Distribution

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
GREEN CROSS MEDICAL SCIENCE CORPORATION	-14.36%	63.18M
BIOMÉRIEUX	-5.86%	12.09B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-4.87%	8.21B
DIASORIN S.P.A.	+5.47%	5.74B
LANTHEUS HOLDINGS, INC.	+27.42%	5.64B
AUTOBIO DIAGNOSTICS CO., LTD.	-9.89%	4.16B
10X GENOMICS, INC.	-58.99%	2.88B
ANDON HEALTH CO., LTD.	+8.97%	2.69B
VITROLIFE AB	-5.19%	2.33B
MYRIAD GENETICS, INC.	+21.58%	2.17B